PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 285/08, 285/135, 417/04, A61K 31/41, 31/495, C07D 213/83, 241/28, 295/155

A1

(11) International Publication Number: WO 98/58919

(43) International Publication Date: 30 December 1998 (30.12.98)

(21) International Application Number: PCT/EP98/04022

(22) International Filing Date: 22 June 1998 (22.06.98)

(30) Priority Data:
97201931.9 24 June 1997 (24.06.97) EP
(34) Countries for which the regional or international application was filed: DE et al.
60/053,003 10 July 1997 (10.07.97) US

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).


(72) Inventors; and
(75) Inventors/Applicants (for US only): STOKBROEKX, Raymond, Antoine [BE/BE]; Rode Kruisstraat 17, B–2340 Beerse (BE). CEUSTERS, Marc, André [BE/BE]; Bredestraat 18, B–3293 Diest (BE). VAN DER AA, Marcel, Jozef, Maria [BE/BE]; Patersstraat 155 bus 1, B–2300 Turnhout (BE). LUYCKX, Marcel, Gerebernus, Maria [BE/BE]; Eksterstraat 24, B–2440 Geel (BE). WILLEMS, Marc [BE/BE]; Merellaan 46, B–2350 Vosselaar (BE). TUMAN, Robert, W. [US/US]; 103 Homestead Court, Chalfont, PA 18914 (US).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
*With international search report.*

(54) Title: ANGIOGENESIS INHIBITING 5–SUBSTITUTED–1,2,4–THIADIAZOLYL DERIVATIVES



(I)



(1)

(57) Abstract

This invention concerns compounds of formula (I), the *N*–oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; $R^1$ is hydrogen, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, $C_{1-6}$alkylthio, amino, mono– or di($C_{1-6}$alkyl)amino, $Ar^1$, $Ar^1NH$–, $C_{3-6}$cycloalkyl, hydroxymethyl or benzyloxymethyl; $R^2$ is hydrogen, $C_{1-6}$alkyl, amino, aminocarbonyl, mono– or di($C_{1-6}$alkyl)amino, $C_{1-6}$alkyloxycarbonyl, $C_{1-6}$alkylcarbonylamino, hydroxy or $C_{1-6}$alkyloxy; $R^3$, $R^4$ and $R^5$ are each independently selected from hydrogen, halo, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, $C_{1-6}$alkyloxy$C_{1-6}$alkyl, $C_{1-6}$alkylthio, $C_{1-6}$alkyloxycarbonyl or $Het^1$; formula (1) is $Ar^2$, $Ar^2CH_2$– or $Het^2$; $Ar^1$ and $Ar^2$ optionally substituted phenyl; $Het^1$ and $Het^2$ are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.